You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 23, 2024

CLINICAL TRIALS PROFILE FOR ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Isosorbide Dinitrate And Hydralazine Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01516346 ↗ Vasodilator Therapy for Heart Failure and Preserved Ejection Fraction Completed National Institute on Aging (NIA) Phase 2 2012-01-01 The main objective is to test the effect of prolonged therapy (24 weeks) with isosorbide dinitrate ± hydralazine on arterial wave reflections (primary endpoint). Secondary endpoints include left ventricular (LV) mass, fibrosis and diastolic function) and exercise capacity (assessed via the 6-minute walk test) in patients with Heart Failure and Preserved Ejection Fraction (HFPEF). We will also test the hypothesis that the reduction in arterial wave reflections induced by vasoactive therapy will correlate with the improvement in exercise capacity, LV mass, fibrosis and diastolic function. Finally, we will assess whether the hemodynamic response to an acute dose of sublingual nitroglycerin (NTG) can predict the sustained changes in the reflected wave and other hemodynamic parameters in response to chronic vasodilator therapy.
NCT01516346 ↗ Vasodilator Therapy for Heart Failure and Preserved Ejection Fraction Completed University of Pennsylvania Phase 2 2012-01-01 The main objective is to test the effect of prolonged therapy (24 weeks) with isosorbide dinitrate ± hydralazine on arterial wave reflections (primary endpoint). Secondary endpoints include left ventricular (LV) mass, fibrosis and diastolic function) and exercise capacity (assessed via the 6-minute walk test) in patients with Heart Failure and Preserved Ejection Fraction (HFPEF). We will also test the hypothesis that the reduction in arterial wave reflections induced by vasoactive therapy will correlate with the improvement in exercise capacity, LV mass, fibrosis and diastolic function. Finally, we will assess whether the hemodynamic response to an acute dose of sublingual nitroglycerin (NTG) can predict the sustained changes in the reflected wave and other hemodynamic parameters in response to chronic vasodilator therapy.
NCT01516346 ↗ Vasodilator Therapy for Heart Failure and Preserved Ejection Fraction Completed Corporal Michael J. Crescenz VA Medical Center Phase 2 2012-01-01 The main objective is to test the effect of prolonged therapy (24 weeks) with isosorbide dinitrate ± hydralazine on arterial wave reflections (primary endpoint). Secondary endpoints include left ventricular (LV) mass, fibrosis and diastolic function) and exercise capacity (assessed via the 6-minute walk test) in patients with Heart Failure and Preserved Ejection Fraction (HFPEF). We will also test the hypothesis that the reduction in arterial wave reflections induced by vasoactive therapy will correlate with the improvement in exercise capacity, LV mass, fibrosis and diastolic function. Finally, we will assess whether the hemodynamic response to an acute dose of sublingual nitroglycerin (NTG) can predict the sustained changes in the reflected wave and other hemodynamic parameters in response to chronic vasodilator therapy.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Isosorbide Dinitrate And Hydralazine Hydrochloride

Condition Name

Condition Name for Isosorbide Dinitrate And Hydralazine Hydrochloride
Intervention Trials
Heart Failure 4
Acute Heart Failure 1
Cardio-Renal Syndrome 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Isosorbide Dinitrate And Hydralazine Hydrochloride
Intervention Trials
Heart Failure 5
Ventricular Dysfunction, Left 1
Ventricular Dysfunction 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Isosorbide Dinitrate And Hydralazine Hydrochloride

Trials by Country

Trials by Country for Isosorbide Dinitrate And Hydralazine Hydrochloride
Location Trials
United States 22
South Africa 1
Denmark 1
Singapore 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Isosorbide Dinitrate And Hydralazine Hydrochloride
Location Trials
Georgia 2
Florida 2
Alabama 2
Massachusetts 2
Pennsylvania 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Isosorbide Dinitrate And Hydralazine Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Isosorbide Dinitrate And Hydralazine Hydrochloride
Clinical Trial Phase Trials
Phase 4 2
Phase 3 2
Phase 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Isosorbide Dinitrate And Hydralazine Hydrochloride
Clinical Trial Phase Trials
Completed 3
Unknown status 2
Active, not recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Isosorbide Dinitrate And Hydralazine Hydrochloride

Sponsor Name

Sponsor Name for Isosorbide Dinitrate And Hydralazine Hydrochloride
Sponsor Trials
Changi General Hospital 1
National Heart Centre Singapore 1
Singapore Clinical Research Institute 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Isosorbide Dinitrate And Hydralazine Hydrochloride
Sponsor Trials
Other 14
Industry 2
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.